Phase Holographic: Sales summary and profit warning for the fiscal year 2024/2025

Phase Holographic Imaging PHI AB ("PHI" or the "Company") today provides an update on the Company’s sales for the fiscal year 2024/2025. Based on the most recent developments and actual order volumes, total sales for the fiscal year are now expected to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.

This revised outlook reflects the latest order intake from the Company’s global distributor Altium SA. While the pace of order placements during the second half of the fiscal year has remained positive, the final volumes will fall slightly below earlier projections.

"While the total order volume for the fiscal year fell short of our previously communicated expectations, it still marks a record-breaking year for PHI, with an increase of sales of about 50 percent compared to 2023/2024 – a clear sign of the growing demand for our solutions", says acting CEO Patrik Eschricht.

The fiscal year 2024/2025 ended on April 30, 2025. PHI will provide a detailed breakdown of the Company’s financial performance in the year-end report, to be published in June 2025.

This disclosure contains information that Phase Holographic is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-05-2025 14:25 CET.

About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC. 

For additional information, please contact:
Patrik Eschricht, CEO
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

Läs mer på Cision